JNJ News Friday, June 26, 2026 0.00 Neutral

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day